NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free GLMD Stock Alerts $0.39 -0.01 (-1.88%) (As of 05:44 PM ET) Add Compare Share Share Today's Range$0.36▼$0.3950-Day Range$0.30▼$0.4252-Week Range$0.26▼$7.80Volume35,002 shsAverage Volume181,436 shsMarket Capitalization$1.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Galmed Pharmaceuticals alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Read More GLMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLMD Stock News HeadlinesApril 24, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)April 19, 2024 | americanbankingnews.comJanOne (NASDAQ:JAN) and Galmed Pharmaceuticals (NASDAQ:GLMD) Head-To-Head AnalysisApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 16, 2024 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.comApril 13, 2024 | fool.comGalmed Pharmaceuticals (NASDAQ: GLMD)April 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 4, 2024 | prnewswire.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023March 15, 2024 | markets.businessinsider.comGalmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver FibrosisApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 15, 2024 | prnewswire.comGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisFebruary 13, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd (GPH.BE)January 3, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd. (GPH.F)November 20, 2023 | finance.yahoo.comGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNovember 4, 2023 | morningstar.comGalmed Pharmaceuticals Ltd GLMDSeptember 26, 2023 | finance.yahoo.comGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisAugust 3, 2023 | nasdaq.comGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08July 14, 2023 | marketwatch.comGalmed Pharma Shares Drop 30% After Public Offering PricesJuly 14, 2023 | seekingalpha.comGalmed shares slump on pricing discounted stock and warrants offeringJuly 14, 2023 | finance.yahoo.comGalmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingJuly 13, 2023 | investorplace.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?July 10, 2023 | finance.yahoo.comGalmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCJuly 3, 2023 | bizjournals.comMadrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drugJune 3, 2023 | benzinga.comGalmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading ActivityJune 1, 2023 | finanznachrichten.deGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsJune 1, 2023 | msn.comRecap: Galmed Pharmaceuticals Q1 EarningsJune 1, 2023 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsMay 17, 2023 | thestreet.comWhy Galmed Pharmaceuticals (GLMD) Stock Is Surging TodaySee More Headlines Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/01/2023Today4/25/2024Next Earnings (Estimated)6/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.29% Return on Assets-44.35% Debt Debt-to-Equity RatioN/A Current Ratio4.81 Quick Ratio4.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book0.15Miscellaneous Outstanding Shares5,050,000Free Float4,046,000Market Cap$2.02 million OptionableNot Optionable Beta0.87 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Allen Baharaff (Age 59)Co-Founder, President, CEO & Chairman Comp: $972.16kMr. Doron Cohen (Age 57)Chief Financial Officer Comp: $245.98kMr. Guy Nehemya (Age 39)COO & Data Protection Officer Comp: $287.04kMr. Yohai Stenzler CPA (Age 41)Chief Accounting Officer Comp: $290.57kDr. Liat Hayardeny (Age 57)Chief Scientific Officer Comp: $47.93kMs. Yael Hollander (Age 41)Vice President of Legal Affairs & Strategy Comp: $134.21kMs. Shani GanonHuman Resources ManagerDr. Tali Gorfine (Age 54)Medical Consultant Comp: $202.76kMore ExecutivesKey CompetitorsBio-PathNASDAQ:BPTHPainReformNASDAQ:PRFXLucy Scientific DiscoveryNASDAQ:LSDIQualigen TherapeuticsNASDAQ:QLGNInMed PharmaceuticalsNASDAQ:INMView All Competitors GLMD Stock Analysis - Frequently Asked Questions Should I buy or sell Galmed Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLMD shares. View GLMD analyst ratings or view top-rated stocks. How have GLMD shares performed in 2024? Galmed Pharmaceuticals' stock was trading at $0.4550 at the beginning of the year. Since then, GLMD stock has decreased by 13.7% and is now trading at $0.3925. View the best growth stocks for 2024 here. Are investors shorting Galmed Pharmaceuticals? Galmed Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 79,000 shares, an increase of 101.5% from the March 31st total of 39,200 shares. Based on an average daily volume of 206,900 shares, the days-to-cover ratio is presently 0.4 days. Approximately 2.2% of the company's stock are short sold. View Galmed Pharmaceuticals' Short Interest. When is Galmed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our GLMD earnings forecast. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its earnings results on Thursday, April, 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter. When did Galmed Pharmaceuticals' stock split? Galmed Pharmaceuticals shares reverse split on the morning of Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLMD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
